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Summary 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, 
VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), 
assessed the risk of “other substances” in food supplements and energy drinks sold in 
Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will 
provide NFSA with the scientific basis while regulating the addition of “other substances” to 
food supplements. 
“Other substances” are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional or physiological effect. It is added 
mainly to food supplements, but also to energy drinks and other foods. VKM has not in this 
series of risk assessments of “other substances” evaluated any claimed beneficial effects 
from these substances, only possible adverse effects. 
The present report is a risk assessment of L-cysteine and L-cystine, and is based on previous 
risk assessments of these amino acids and articles retrieved from a comprehensive literature 
search. In this report L-cysteine and L-cystine are often termed merely cysteine and cystine, 
respectively. 
L-cysteine is a central compound in sulphur metabolism in the human body. L-cysteine is a 
conditionally essential sulphur-containing amino acid, obtained from L-methionine and from 
serine. Sulphur-containing amino acids are mainly found in cereal proteins and animal 
proteins, and less abundantly in pulses. Cysteine may occur in proteins either as cysteine 
itself or as cystine. Cystine is the disulphide dimer of cysteine, and is a more stable 
compound than cysteine.  
According to information from the Norwegian Food Safety Authority (NFSA), cysteine and 
cystine are ingredients in food supplements purchased in Norway and NFSA has requested a 
risk assessment of the following doses of cysteine and cystine in food supplements: L-
cysteine 10 mg/day and L-cystine 250, 500, 750 and 1000 mg/day. The mean usual daily 
intake of cysteine in the USA for all life stage- and gender groups is 1.0 g/day (NHANES II, 
USA). 
Because there are few intervention studies with cysteine or cystine, studies with N-
acetylcysteine (or N-acetyl-L-cysteine, NAC), which is readily converted to cysteine, is 
included in this risk assessment. NAC is used as a pharmaceutical drug for various 
conditions, mainly as mucolytic agent, as paracetamol antidote, and has been included in 
numerous clinical trials.  
Most of the cited studies have tested NAC in doses of about 600-1200 mg/day. The study 
groups have been various patient groups which included children, adolescents, adults and 
elderly, however relatively few studies have been conducted in children. In the randomised 
controlled trials there have been no differences in severe adverse events between the 
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placebo and NAC-groups. The adverse effects reported are generally limited to mild 
gastrointestinal symptoms. 
The dose 1200 mg of NAC yields maximum 900 mg of L-cysteine or L-cystine. In adults, it is 
well documented that doses up to 900 mg per day for one year (corresponding to 13 mg/kg 
bw/day in a 70 kg adult) is without appreciable health risk. The data for doses above 
900 mg/day are more scarce.  
There are no data indicating that children and adolescent are more vulnerable than adults 
for L-cysteine or L-cystine. No tolerance level is set for cysteine or cystine specifically for 
children or adolescents, but an assumption is made that these age groups have similar 
tolerance per kg body weight as adults. 
VKM concludes that:  
 In adults (≥18 years), the specified doses 10 mg/day L-cysteine and 250, 500 and 
750 mg/day L-cystine in food supplements are considered to be unlikely to cause 
adverse health effects, whereas the dose 1000 mg L-cystine per day may represent a 
risk of adverse health effects. 
 In adolescents (14 to <18 years), the specified doses 10 mg/day L-cysteine and 250, 
500 and 750 mg/day L-cystine in food supplements are considered to be unlikely to 
cause adverse health effects in adolescents, whereas the dose 1000 mg L-cystine per 
day may represent a risk of adverse health effects. 
 In children (10 to <14 years), the specified doses 10 mg/day L-cysteine and 250 and 
500 mg/day L-cystine in food supplements are considered to be unlikely to cause 
adverse health effects, whereas the doses 750 and 1000 mg L-cystine per day may 
represent a risk of adverse health effects.  
Children below 10 years were not included in the terms of reference. 
Short summary: 
The Norwegian Scientific Committee for Food Safety (VKM) has, at the request of the 
Norwegian Food Safety Authority, assessed the risk of specified doses of L-cysteine and L-
cystine in food supplements. VKM concludes that: 
 In adolescents (14 to <18 years) and adults (≥18 years), the specified doses 
10 mg/day L-cysteine and 250, 500 and 750 mg/day L-cystine in food supplements 
are considered to be unlikely to cause adverse health effects, whereas the dose 
1000 mg L-cystine per day may represent a risk of adverse health effects. 
 In children (10 to <14 years), the specified doses 10 mg/day L-cysteine and 250 and 
500 mg/day L-cystine in food supplements are considered to be unlikely to cause 
adverse health effects, whereas the doses 750 and 1000 mg L-cystine per day may 
represent a risk of adverse health effects.  
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Sammendrag på norsk 
På oppdrag for Mattilsynet har Vitenskapskomiteen for mattrygghet (VKM) vurdert risiko ved 
tilsetting av “andre stoffer” i kosttilskudd og energidrikk som selges i Norge. VKM har 
risikovurdert ulike bruksdoser oppgitt fra Mattilsynet. Disse risikovurderingene vil gi 
Mattilsynet vitenskapelige grunnlag for å regulere “andre stoffer” i kosttilskudd. 
“Andre stoffer” er stoffer som har en ernæringsmessig eller fysiologisk effekt, og som ikke er 
vitaminer og mineraler. De tilsettes i hovedsak til kosttilskudd, men også til energidrikker og 
andre næringsmidler. I disse risikovurderingene har VKM ikke sett på potensielle gunstige 
helseeffekter, men kun vurdert mulige negative helseeffekter. 
I denne rapporten har VKM vurdert risiko ved L-cystein og L-cystin. Risikovurderingen er 
basert på tidligere risikovurderinger av disse aminosyrene og artikler som er funnet ved et 
omfattende litteratursøk. Videre i denne rapporten omtales L-cystein og L-cystin ofte kun 
som henholdsvis cystein og cystin. 
L-cystein er en sentral forbindelse i kroppens metabolisme av svovel. L-cystein er en semi-
essensiell svovelholdig aminosyre som kan dannes fra L-metionin og serin. I kosten finner vi 
de svovelholdige aminosyrene hovedsakelig i kornprodukter og animalsk protein, og i mindre 
grad i belgvekster som bønner og linser. Cystein kan forekomme i proteiner enten som 
cystein eller som cystin. Cystin består av to cysteinmolekyler, og er en mer stabil forbindelse 
enn cystein. 
Ifølge informasjon fra Mattilsynet er cystein og cystin ingredienser i kosttilskudd som selges i 
Norge. Oppdraget fra Mattilsynet var å risikovurdere følgende doser i kosttilskudd: L-cystein 
10 mg/dag og L-cystin 250, 500, 750 og 1000 mg/dag. Gjennomsnittlig inntak av cystein fra 
kosten i USA i alle aldersgrupper, inkludert både menn og kvinner, er 1,0 g/dag (NHANES II, 
USA). 
Ettersom det finnes få intervensjonsstudier med cystein eller cystin, er studier med N-
acetylcystein (eller N-acetyl-L-cystein, NAC) som lett konverteres til cystein, inkludert i denne 
risikovurderingen. NAC er brukt som legemiddel for en rekke tilstander, hovedsakelig som 
slimløsende middel, og det er en viktig antidot ved paracetamolforgifting, og inngår i mange 
kliniske studier.  
I de fleste studiene er NAC undersøkt i doser på omlag 600-1200 mg/dag, men med et 
dosespenn fra ca. 600 til 2400 mg/dag. Gruppene som er undersøkt er for det meste 
varierende pasientgrupper i ulike aldre; barn, unge, voksne og eldre, men det er relativt få 
studier med barn. I de randomiserte kliniske studiene finner man ingen signifikant forskjell i 
alvorlige negative helseeffekter mellom placebo- og NAC-gruppene. Negative helseeffekter 
som er rapport i studiene er stort sett begrenset til milde gastrointestinale symptomer. 
En dose på 1200 mg NAC gir maksimum 900 mg L-cystein eller L-cystin. Det er godt 
dokumentert at 900 mg/dag oralt administrert tilskudd av cystein eller cystin i opptil ett år 
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hos voksne (tilsvarer 13 mg/kg kroppsvekt/dag i en voksen person som veier 70 kg) 
sannsynligvis ikke vil forårsake negative helseeffekter. Data for doser over 900 mg/dag er 
mer usikkert.  
Det er ikke framkommet data som indikerer at barn og ungdom er mer sårbare enn voksne 
for L-cystein eller L-cystin. Det er ikke fastsatt et eget toleransenivå for barn og unge, men 
forutsatt at disse aldersgruppene har samme toleranse per kg kroppsvekt som voksne. 
Vitenskapskomiteen for mattrygghet (VKM) konkluderer med at: 
 For voksne (≥18 år) er det usannsynlig at dosene 10 mg/dag L-cystein og 250, 500 
og 750 mg/dag L-cystin i kosttilskudd vil forårsake negative helseeffekter, mens en 
dose på 1000 mg L-cystin per dag vil kunne representere en risiko for negative 
helseeffekter. 
 For ungdom (14 til <18 år) er det usannsynlig at dosene 10 mg/dag L-cystein og 
250, 500 og 750 mg/dag L-cystin i kosttilskudd vil forårsake negative helseeffekter, 
mens en dose på 1000 mg L-cystin per dag vil kunne representere en risiko for 
negative helseeffekter. 
 For barn (10 til <14 år) er det usannsynlig at dosene 10 mg/dag L-cystein og 250 og 
500 mg/dag L-cystin i kosttilskudd vil forårsake negative helseeffekter, mens doser 
på 750 og 1000 mg L-cystin per dag vil kunne representere en risiko for negative 
helseeffekter. 
Barn under 10 år inngår ikke i oppdraget. 
Kort sammendrag:  
Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag for Mattilsynet har vurdert risiko 
ved inntak spesifikke doser av L-cystein og L-cystin i kosttilskudd. VKM konkluderer med at: 
 For ungdom (14 til <18 år) og voksne (≥18 år) er det usannsynlig at dosene 
10 mg/dag L-cystein og 250, 500 og 750 mg/dag L-cystin i kosttilskudd vil forårsake 
negative helseeffekter, mens en dose på 1000 mg L-cystin per dag vil kunne 
representere en risiko for negative helseeffekter. 
 For barn (10 til <14 år) er det usannsynlig at dosene 10 mg/dag L-cystein og 250 og 
500 mg/dag L-cystin i kosttilskudd vil forårsake negative helseeffekter, mens doser 
på 750 og 1000 mg L-cystin per dag vil kunne representere en risiko for negative 
helseeffekter. 
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Abbreviations and glossary 
Abbreviations 
AESAN  - Spanish Agency for Food Safety and Nutrition 
ANSES  - French Agency for Food, Environmental and Occupational Health and Safety 
AUC  - area under the curve 
bw  - body weight 
COPD  - chronic obstructive pulmonary disease 
CRP  - C-reactive protein 
EFSA  - European Food Safety Authority 
FDA  - Food and Drug Administration, USA 
GI  - gastrointestinal 
HDL  - high density lipoprotein 
IOM  - Institute of Medicine, USA 
LD50  - lethal dose for 50% of the animals 
LDL  - low density lipoprotein 
NAC  - N-acetylcysteine 
NADH  - reduced nicotinamide adenine dinucleotide 
NFSA  - Norwegian Food Safety Authority [Norw.: Mattilsynet] 
NHANES - National Health and Nutrition Examination Survey 
NOAEL  - no observed adverse effect level 
UL  - tolerable upper intake level 
VKM  - Norwegian Scientific Committee for Food Safety [Norw.: Vitenskapskomiteen 
for Mattrygghet] 
VLDL  - very low density lipoprotein 
WHO  - World Health Organization 
Glossary 
“Other substances”: a substance other than a vitamin or mineral that has a nutritional or 
physiological effect (European Regulation (EC) No. 1925/2006, Chapter I, Article 2; 
https://www.anses.fr/sites/default/files/documents/NUT2007sa0314EN.pdf). 
“Negative health effect” and “adverse health effect” are broad terms and World Helath 
Organization (WHO) has established the following definition for “adverse effect”: a change in 
morphology, physiology, growth, development, reproduction or life span of an organism, 
system or (sub)population that results in an impairment of functional capacity, an 
impairment of the capacity to compensate for additional stress, or an increase in 
susceptibility to other influences (WHO, 1994). 
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An adverse event is considered serious if it: 
 results in death 
 is life-threatening 
 requires or prolongs hospitalisation 
 is a congenital anomaly or birth defect 
 is a persistent or significant disability/incapacity 
 is another serious or important medical event 
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Background as provided by the 
Norwegian Food Safety Authority 
“Other substances” are substances other than vitamins and minerals, with a nutritional 
and/or physiological effect on the body. “Other substances” are mainly added to food 
supplements, but these may also be added to other foods and beverages, such as sports 
products and energy drinks. Ingestion of these substances in high amounts presents a 
potential risk for consumers. 
In Norway, a former practice of classification of medicines had constituted an effective 
barrier against the sale of potentially harmful “other substances”. Ever since this practice 
was changed in 2009, it has become challenging to regulate and supervise foods with added 
“other substances”. Meanwhile, in the recent years, the Norwegian market has witnessed a 
marked growth in the sales of products containing “other substances”. In 2011, food 
supplements containing “other substances” constituted more than 50% of the market share. 
While at the EU level, these substances fall under the scope of the European Regulation (EC) 
No. 1925/2006 on the addition of vitamins, minerals and certain other substances to foods 
and the European Regulation (EC) No 258/97 concerning novel foods and novel food 
ingredients, “other substances” remain largely unregulated. In order to ensure safe use of 
“other substances” many countries have regulated their use at a national level. For example, 
Denmark regulates these substances in a positive list i.e. a list of substances with maximal 
daily doses, permitted for use in food supplements and other foods 
(https://www.retsinformation.dk/Forms/R0710.aspx?id=163394).  
NFSA is working on the establishment of a regulation on the addition of “other substances” 
to foods at a national level. The regulation will include a list of substances with permitted 
maximal doses, based on the substances and doses found in products on the Norwegian 
market. NFSA has therefore requested the Norwegian Scientific Committee for Food Safety 
(VKM) to assess the safety of “other substances” found on the Norwegian market. NFSA, in 
consultation with the industry, has compiled a list of “other substances” found in products 
marketed in Norway. Only substances with a purity of minimum 50% or concentrated 40 
times or more have been included in the list. Substances regulated by other legislations like 
those for novel foods, food additives, aromas, foods for special medical purposes, etc. have 
been excluded from the list. 
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Terms of reference as provided by the 
Norwegian Food Safety Authority 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of L-cysteine and L-cystine in food supplements 
at the following doses:  
L-cysteine: 10 mg/day 
L-cystine: 250, 500, 750 and 1000 mg/day 
NFSA requested VKM to assess the safety of “other substances” (in accordance to the 
guidance document developed in Phase 2) at the doses specified (Phase 3). 
Safety assessments for “other substances” present in food supplements shall be carried out 
for a general population, ages 10 years and above. 
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Assessment 
1 Introduction 
“Other substances” are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional and/or physiological effect, and may 
be added to food supplements or e.g. energy drinks.  
This risk assessment regards the substances L-cysteine and L-cystine per se, and no specific 
products. In this report L-cysteine and L-cystine are often termed merely cysteine and 
cystine, respectively. 
VKM has in this series of risk assessments of “other substances” not evaluated any claimed 
beneficial effects from these substances, but merely possible adverse effects at specified 
doses used in Norway.  
According to information from the Norwegian Food Safety Authority (NFSA), cysteine and 
cystine are ingredients in food supplements purchased in Norway and NFSA has requested a 
risk assessment of the following doses of cysteine and cystine in food supplements: L-
cysteine 10 mg/day and L-cystine 250, 500, 750 and 1000 mg/day. 
L-cysteine is a central compound in sulphur metabolism in the human body. L-cysteine is a 
conditionally essential sulphur-containing amino acid, obtained from L-methionine and from 
serine. In normal physiological conditions the body is able to obtain L-cysteine in sufficient 
quantity. However premature babies cannot synthesise it and must obtain it through diet. 
The thiol groups (-SH) of two molecules of cysteine are readily oxidised to yield the 
disulphide group of cystine. Cystine plays a special role in the structure of proteins. Cysteine 
and cystine are interconvertable and are therefore considered together in this report. 
NFSA has requested assessment of the L-isomers of the two amino acids. There are very few 
published studies investigating the effects of L-cysteine or L-cystine. However, N-
acetylcysteine (or N-acetyl-L-cysteine, NAC) is used as a pharmaceutical drug for various 
conditions, mainly as mucolytic agent, as a paracetamol antidote, and is included in 
numerous clinical trials. The acetyl-group in NAC acts merely as a molecule stabiliser, and is 
not believed to change the physiological properties, and studies with NAC are therefore 
included in this risk assessment. 
The common mean daily intake of cysteine in the USA for all life stage and gender groups is 
about 1.0 g/day (NHANES II, USA) and daily turnover is about 7 g/day in a 70 kg person 
(Fukagawa et al., 1998). 
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2 Hazard identification and 
characterisation 
2.1 Literature 
In this risk assessment we have evaluated previous risk assessments of cysteine and articles 
retrieved from a comprehensive literature search.  
 Previous risk assessments 2.1.1
Risks related to L-cysteine has previously been evaluated by the Institute of Medicine (IOM) 
in USA in 2005, the European Food Safety Authority (EFSA) as flavouring substance and in 
another EFSA opinion as food additive for technical purposes in foods intended for infants 
and young children in 2006 and 2007, the French Agency for Food, Environmental and 
Occupational Health & Safety (ANSES) and VKM in 2011 and the Scientific Committee of the 
Spanish Agency for Food Safety and Nutrition (ASEAN) for use in food supplements in 2012 
(AESAN, 2012; ANSES, 2011; EFSA, 2006; EFSA, 2007; IOM, 2005; VKM, 2011). N-acetyl-L-
cysteine was evaluated for the use in foods for special medical purposes by EFSA in 2003 
(EFSA, 2003). 
The opinions from EFSA in 2006 and 2007 evaluate L-cysteine and L-cystine in amounts 
magnitude lower than the doses relevant for this opinion, and the conclusions from these 
EFSA-reports are therefore not relevant for our purpose. However, human and animal 
toxicological data from these opinions are listed in the tables below. 
Opinion related to N-acetyl-L-cysteine for use in foods for particular nutritional 
uses and in foods for special medical purposes. EFSA, 2003 
The opinion by EFSA in 2003 evaluated the extent to which NAC could be used as a source 
for L-cysteine in foods for particular nutritional uses and for special medical purposes. The 
opinion concluded that including NAC in the list of substances permitted for foods for special 
medical purposes was acceptable. However, due to some uncertainties regarding “a 
potential” prooxidative effect of NAC, they did not recommend NAC as general replacement 
for L-cysteine in foods (EFSA, 2003). 
Dietary reference intakes, tolerable upper intake levels for individual amino acids, 
Institute of Medicine. USA, 2005 
The IOM (2005) concluded that the data on adverse effects of L-cysteine and L-cystine 
intake from supplements were not sufficient for a dose-response assessment and derivation 
of a tolerable upper intake level (UL). L-cysteine has been classified as a neuro excitotoxin 
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because of its interaction with N-methyl D-aspartate receptors (Olney, 1994 cited in IOM, 
2005). Single oral doses of 5-10 g of cysteine have produced nausea and light-headedness in 
healthy humans (Carlson et al., 1989 cited in IOM, 2005). 
Opinion of the French Agency for Food, Environmental and Occupational Health & 
Safety on the assessment of the risks associated with substances with nutritional 
or physiological effects with a view to restricting or prohibiting their use in 
foodstuffs. France, 2011 
ANSES (2011) elaborates on the topic of amino acid metabolism and states that “on a 
nutritional and metabolic level, consumption of an amino acid at levels much higher than 
other amino acids, and much higher than the corresponding quantitative requirements for 
protein synthesis, induces changes in circulating pools, changes in functions directly 
controlled by the amino acids, the substantial entry of these amino acids into catabolic 
pathways (sometimes in “secondary”metabolic pathways) and the activation of excretion 
pathways. “ Specific for cysteine, and based on animal experiments, this ANSES report lists 
hypercholesterolemia, fatty liver and neurotoxicity as possible adverse effects of high intakes 
of cysteine. 
VKM report on risk categorisation of amino acids. Norway, 2011 
In 2011, VKM conducted a risk categorisation of about 30 amino acids and amino acid 
compounds based on potential health risks related to high intakes of the amino acids. 
Cysteine, cystine and NAC were suggested categorised as substances with moderate risk 
(VKM, 2011). This categorisation was based on no scientific documentation other than the 
general knowledge that amino acids in general are bioactive compounds. No studies with 
cysteine or cysteine were identified. It was emphasised that the VKM report from 2011 has 
several limitations and can only be regarded as an initial screening and not as risk 
assessment of the many amino acids. 
Report of the Scientific Committee of the Spanish Agency for Food Safety and 
Nutrition on the use conditions for certain substances other than vitamins, 
minerals and plants in food supplements. Spain, 2012 
AESAN (2012) noted that a maximum daily amount of 300 mg of L-cysteine is lower than the 
requirements of L-methionine + L-cysteine established by WHO and is very far from the 
doses of L-cysteine that cause dizziness and nausea. ASEAN therefore considered it 
acceptable from the safety point of view for use as a food supplement. An explanation for 
the conclusion on 300 mg is not given in the report, but we assume that ASEAN was 
requested to evaluate if the dose of 300 mg was safe. 
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2.1.1.1 Overview of some toxicity studies in previous risk assessments 
Table 2.1.1-1 - 2.1.1-3 gives an overview of various toxicity studies with cysteine or cystine cited in 
previous risk assessment. 
Table 2.1.1-1: Overview of genotoxicity studies (in vitro) with cysteine or cystine cited in previous 
risk assessments. 
Reference Substance Test cystem, test object Concentration Result 
Sargentini & Smith, 
1986 
Cystine Mutagenesis assay (plate 
method) 
2 mM (481 
µg/ml) 
No effects 
observed  
Stich et al., 1981 L-cysteine Chromosomal aberration 
assay, Chinese hamster ovary 
cells 
5x10-4 M (61 
µg/ml) 
No effects 
observed 
Speit et al., 1980 L-cysteine Sister chromatid exchange, 
V79) Chinese hamster ovary 
cells 
Up to 10-3 M 
(121 µg/ml) (2 
doses tested) 
No effects 
observed 
Table 2.1.1-2: Overview of acute toxicity studies with cysteine or cystine cited in previous risk 
assessments. 
Reference Substance Species; sex Route LD50 (mg/kg bw) 
Kawai et al., 1978 Cystine Rat; M, F Oral >25,000 
Sprince et al., 1974 L-cysteine Rat, M Gavage 1890 
Takasaki et al., 1973 L-cysteine Rat; M, F Oral M:6350 
F: 5580 
Takasaki et al., 1973 L-cysteine Mouse Oral M: 3550 
F: 4200 
M: male 
F: female 
Table 2.1.1-3: Overview of subacute/subchronic/chronic/carcinogenicity studies and developmental 
and reproductive toxicity studies with cysteine or cystine cited in previous risk assessments. 
Reference Substance Species; sex 
No/group 
Route Dose level 
(mg/kg 
bw/day) 
Duration NOAEL 
(mg/kg bw/day) 
Kawai et al., 
1978 
Cystine Rat; M, F 4/14 
or 20 
Oral 0, 100, 300, 
600 or 3000 
93 days 600 
Takasaki et 
al., 1973 
L-cysteine Mouse; 3/8-12 Gavage 0, 200, 
1000 or 
3000 
30 days No NOAEL derived, 
adverse effects 
observed at all doses 
tested 
Takasaki et 
al., 1973 
L-cysteine Rat; 3/9-12 Gavage 0, 200, 
1000 or 
5000 
30 days No NOAEL derived, 
adverse effects 
observed at all doses 
tested 
Takasaki et 
al., 1973 
L-cysteine Rat; M 3/10-12 Gavage 0, 100, 500 
or 2000 
6 months No NOAEL derived, 
adverse effects 
observed at all doses 
tested 
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Reference Substance Species; sex 
No/group 
Route Dose level 
(mg/kg 
bw/day) 
Duration NOAEL 
(mg/kg bw/day) 
Frape et al., 
1971 
L-cysteine Rat; M, F 1-3/4-
72 
Diet 0 or 3500 
ppm in diet 
(equivalent 
to 0 or 175 
mg/kg 
bw/day L-
cysteine) 
6-
generation 
reproducti
on 
3500 ppm in diet 
(equivalent to 175 
mg/kg bw/day) 
M: male 
F: female 
We have not described these animal studies further than the information given in the tables 
in the present report. The original studies were not accessible and in Japanese and the 
information is taken from the EFSA report (EFSA2008). No further details on the adverse 
effects were given in the report. Animal studies are briefly discussed in chapter 2.4. 
 Literature search 2.1.2
Literature searches were performed in MEDLINE, EMBASE and Global Health in order to 
retrieve publications on adverse effects caused by cysteine and cystine. These databases 
were chosen to ensure comprehensive study retrieval. The literature searches were 
performed by a librarian 5 March 2015. The strategy for the search is included in Appendix 1. 
2.1.2.1 Publication selection and data extraction 
The study types for inclusion in this opinion have been human studies. Animal studies were 
not included in the literature search due to numerous human studies and because several 
animal studies were included in previous risk assessments. However, we critically reviewed 
animal studies included in the previous risk assessments. The criteria for inclusion were: 
 Cysteine or cystine in relation to adverse effect must be addressed in the abstracts of 
the paper 
 Outcome not affected by other substances than cysteine or cystine 
 Oral route of exposure to cysteine or cystine in human studies 
 Human studies were performed in apparently healthy individuals or patient groups 
who are assumed to have normal cysteine and cystine absorption and metabolism. 
In vitro studies were not included. Also papers in languages other than English, Norwegian, 
Danish or Swedish were excluded. 
The literature search 5 March 2015 identified 2525 articles.  
Study titles and abstracts were first reviewed by the secretariat, followed by a further 
selection by the author of this report, resulting in selection of 55 full text articles. After 
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review of the available full text articles using the same inclusion criteria as above, 19 articles 
were included.  
Because of the previously described effect of cysteine on cholesterol in animal studies, a 
separate, Pubmed search on studies on cholesterol and cysteine or cystine was performed 
26 May 2015 (search terms: cholesterol OR Lipid OR lipoprotein AND cysteine or cysteine). 
One additional human study and two animal studies were identified. 
A final total of 22 publications (20 human and 2 animal studies) were identified and included 
in the results in this report (see Figure 2.1.2.1-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.3.1-1: Flow chart for publication selection for cysteine and cystine literature search. 
2.2 General information 
 Chemistry 2.2.1
L-cysteine C3H7NO2S (CH2SH-CHNH2-COOH) is a conditionally essential sulphur-containing 
amino acid. L-cystine is the dimer of L-cysteine. The CAS numbers are 52-90-4 (L-cysteine) 
Main search 
The publications were identified searching 
Medline, Embase and Global Health 
Titles and abstracts 
n = 2525 
  
Full text 
n = 55 
Manual search in 
Pubmed 
3 additional 
publications were 
identified 
Publications not fulfilling the 
inclusion criteria were excluded 
n = 36 
Publications not fulfilling the 
inclusion criteria were excluded 
n = 2470 
22 publications 
included 
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and 56-89-3 (L-cystine). Figure 2.2.1-1 shows the structural formulas for these amino acids 
and their interconvertion reaction. 
 
Figure 2.2.1-1: Structural formulas of cysteine and cystine and their interconversion reaction. 
NAC C5H9NO3S is the N-acetyl derivate of cysteine. Figure 2.2.1-2 shows the structural 
formula for NAC. 
 
Figure 2.2.1-2: Structural formula of NAC. 
 Occurrence 2.2.2
In the normal diet, the amino acids are ingested as components of food proteins and not as 
free acids. Sulphur-containing amino acids are mainly found in cereal proteins and animal 
proteins, and less abundantly in pulses. Cysteine may occur in proteins either as cysteine 
itself or as cystine. In addition cysteine and cystine are available in food supplements.  
According to Fukagawa et al. (1998), cysteine turnover in elderly is 35.6 µmol/kg/hour, 
corresponding to approximately 7 g/day in a 70 kg person. 
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Most of the commercially available L-cysteine is produced from hydrolysis of human hair, 
poultry feathers or pig hair (Berehoiu et al., 2013). 
2.3 Absorption, distribution, metabolism and excretion 
 In humans 2.3.1
Cysteine may occur in proteins either as cysteine itself or as cystine. Cystine passes through 
the gastrointestinal (GI) tract and is immediately reduced to two cysteine molecules upon 
cell entry. L-cystine is converted to L-cysteine through cystine reductase, which requires 
NADH as cofactor.  
L-cysteine is a central compound in sulfur metabolism in the human body. In humans, L-
cysteine is synthesised from L-methionine and L-serine. L-cysteine is degraded to pyruvate in 
two steps, by desulphurisation and transamination. Cysteine can be metabolised to form 
taurine and carbon dioxide through the cysteinsulfinate pathway, where the initial step is 
oxidation of cysteine to cysteine sulfinate. This step is catalysed by cysteine dioxygenase. 
Cysteine sulfinate may then be decarboxylated to form taurine or it may be metabolised via 
the putative intermediate beta-sulfinylpyruvate to pyruvate and sulfite and then to 
carbondioxide and sulfate, illustrated in Figure 2.3.1-1 (Stipanuk et al., 2006).  
L-cysteine is also involved in the synthesis of coenzyme A and glutathione.  
 
Figure 2.3.1-1: Metabolism of cysteine in the human body (Source:Stipanuk et al. (2006)) 
Absorption and metabolism of NAC 
The EFSA opinion on N-Acetyl-L-cysteine for use in foods for particular nutritional uses and in 
foods for special medical purposes from 2003 elaborated on the absorption and metabolism 
of NAC (EFSA, 2003). The following is cited from this opinion: “In humans, single or multiple 
oral doses of NAC resulted in measurable plasma levels of NAC in most subjects and in 
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significant increases of plasma L-cysteine or L-cystine, total and protein SH groups, non-
protein SH groups and disulphide-bound thiols, showing that NAC is metabolised to cysteine 
and further metabolites including incorporation into proteins. Only a small percentage of the 
intact molecule NAC arrives in plasma and tissues (Maddock, 1980). The oral bioavailability 
in humans, calculated as area under the curve (AUC): AUC (oral)/AUC (i.v.), varied between 
6 and 10%, probably due to the fast metabolism in the gut wall and liver (Borgström et al., 
1986).”  
NAC is readily converted in cells to cysteine (Raftos et al., 2007). NAC is deacetylated in 
isolated hepatocytes and supports glutathione synthesis in these cells (Thor et al., 1979). 
Also, human endothelial cells, rat lung, intestinal, and liver homogenates, and human liver 
homogenates catalyse the deacetylation of NAC (Sheffner, 1966; Sjodin et al., 1989). 
Bioequivalence NAC to L-cysteine  
The following is cited from the EFSA opinion on NAC from 2003: “A direct comparison of 
plasma bioavailability of L-cysteine from oral NAC and L-cysteine has not been undertaken. 
However, NAC was found to be bioequivalent to an isomolar amount of L-cystine in 
stimulating growth of male weanling rats fed enteral formula (Baker and Han, 1993). In 
accordance with earlier studies, the partial conversion of orally administered NAC to plasma 
L-cysteine has been demonstrated in humans by showing that the oral administration of 
600 mg NAC resulted not only in the appearance of NAC in plasma in a mean maximum 
concentration of 4.6 µM, but also in an increase of the mean cysteine plasma concentration 
from 10 µM to a maximum level of 18.6 µM after one hour (Tsikas et al., 1998)”. 
 In animals 2.3.2
The following is also cited from the EFSA opinion on NAC from 2003: “NAC is almost 
completely absorbed, when orally administered to rats, only 3% of the radioactivity of 35 S-
NAC being excreted in the faeces (Bonanomi and Gazzaniga, 1980). It is effectively 
deacetylated by intestinal epithelial cells of rats (Cotgreave et al., 1987) and rat liver, lung 
and intestine homogenates (Sjodin et al., 1989). A metabolic study with 35 S-NAC in rats 
showed that cysteine and cystine were the major metabolites in the liver and inorganic 
sulphate was the major urinary excretion product (Sheffner, 1966). Another study in rats 
demonstrated that the levels of cysteine and inorganic sulphite in the portal vein plasma 
were five and three times higher than that of NAC, respectively, following intraintestinal 
administration of NAC (Cotgreave et al., 1987).” 
2.4 Toxicological data/Adverse effects 
 Human studies 2.4.1
In humans, oral doses of 5 and 10 g of L-cysteine provoked nausea and slight dizziness 
(Carlson et al., 1989). In addition, healthy people who were administered with increasing 
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doses of up to 20 g of L-cysteine (with tranylcypromine) exhibited fatigue, dizziness, nausea 
and insomnia depending on the dose (Davis et al., 1972). 
Table 2.4.1-1: Overview of human studies investigating NAC and adverse health effects. 
Reference Participant 
characteristics, 
age groups 
Country  Number in 
treatment 
group 
Doses, 
mg/day 
Main endpoints Length of 
follow-up 
Adverse effects 
NAC Control 
RCTs         
Kopke et al. 
(2015) 
Hearing loss in 
marine recruits, 18-
35 years 
USA 317 317 2700 Hearing 13 days Several reported, 
but no differences 
between the 
groups. No severe 
adverse events 
Mousavi et 
al. (2015) 
Methamphetamine 
addicts, mean age 29 
years 
Iran 23 23 1200 Methamphetamine 
craving 
4 weeks 
(crossover) 
No differences 
between the 
groups. No severe 
adverse events 
Berk et al. 
(2014) 
Depressed, mean age 
50 years 
Australia 135 134 2000 Change in 
symptom scale 
12 weeks The NAC group 
had a greater rate 
of gastrointestinal 
and 
musculoskeletal 
adverse events 
Zheng et al. 
(2014) 
COPD patients, mean 
age 67 years 
China 504 502 1200 Exacerbations 1 year Several, reported. 
9% had adverse 
events regarded 
by the 
investigators as 
possibly related to 
study products, as 
did 7% patients 
who received 
placebo 
Tse et al. 
(2013) 
COPD patients, 66 
years 
Hong 
Kong 
58 62 1200 Lung function, 
symptom scale 
1 year Several reported, 
but no differences 
between the 
groups. No severe 
adverse events 
Gray et al. 
(2012) 
Cannabis dependent, 
mean age 19 years 
USA 58 58 2400 Cannabis use 8 weeks No differences 
between the 
groups. No severe 
adverse events 
Hardan et 
al. (2012) 
Children with autism 
3-11 years 
USA 14 15 900-2700 Symptom scale 12 weeks Several reported, 
but no differences 
between the 
groups. No severe 
adverse events 
Ferreira et 
al. (2011) 
Healthy volunteers, 
mean age 30 years 
USA 8 7 700-1500 Handgrip exercise Short, 
days 
No differences 
between the 
groups. No severe 
adverse events 
Dauletbaev 
et al. 
(2009) 
Cystic fibrosis 
patients, mean age 
28 years 
 11 10 700 or 
2800 
Safety and clinical 
parameters 
12 weeks No differences 
between the 
groups. No severe 
adverse events 
Grant et al. 
(2009) 
Trichotillomania 
patients, mean age 
34.3 years 
USA 25 25 1200/ 
2400 
Symptom score 12 weeks Some GI were 
reported. No 
differences 
between the 
groups. No severe 
adverse events 
Berk et al. 
(2008a) 
Schizophrenia 
patients, mean age 
36.6 years 
Australia 69 71 1000 Change in 
symptom scale 
24 weeks Several reported. 
None of these 
related to NAC 
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Reference Participant 
characteristics, 
age groups 
Country  Number in 
treatment 
group 
Doses, 
mg/day 
Main endpoints Length of 
follow-up 
Adverse effects 
NAC Control 
Berk et al. 
(2008b) 
Bipolar disorder 
subjects, 45 years 
Australia 38 37 2000 Change in 
symptom score 
24 weeks Several reported. 
No severe related 
to NAC 
Bachh et al. 
(2007) 
COPD patients, mean 
age 62 years 
India 50 50 600 Lung function and 
exacerbations 
1 year There were no 
differences 
between the 
groups, but the 
type of adverse 
effects were not 
mentioned 
LaRowe et 
al. (2006) 
Cocaine dependent, 
37 years 
USA 11  11 1200 Safety and 
biochemical 
parameters 
2 days 
(crossover) 
Several reported, 
but no differences 
between groups. 
No severe adverse 
events 
Zuin et al. 
(2005) 
COPD patients, mean 
age 66 years 
Italia 42 39/41 600/1200 
mg 
Lung function, 
symptoms, CRP- 
and interleukin- 
levels 
10 days Several reported, 
but no differences 
between the 
groups. No severe 
adverse events 
Pela et al. 
(1999) 
COPD, patients, 
mean age 66 years 
Italia 85 84 600 Exacerbations 6 months No differences 
between the 
groups. No severe 
adverse events 
De Flora et 
al. (1997) 
Elderly with chronic 
illness 
Italia 133 129 1200 Episodes of 
influenza 
6 months No differences 
between the 
groups. No severe 
adverse events 
Meta-
analysis 
        
Chalumeau 
and 
Duijvestijn 
(2013) 
Children with 
respiratory infections 
World-
wide 
831 249 Approx 
500 mg 
(max) 
Efficacy of 
mucolytic drugs 
given during acute 
respiratory 
infections 
 Several 
biochemical and 
clinical 
parameters were 
recorded. Only 
mild GI symptoms 
were associated 
with NAC 
Other 
human 
studies 
        
Mallet et al. 
(2011) 
Children with 
respiratory infections, 
0-2 years 
France 30 No Approx 
500 mg 
(max) 
Respiratory 
Paradoxical 
Adverse Drug 
Reactions 
between 1989 
and 2008 
Short, 
therapeutic 
use of NAC 
Only paradoxical 
drug reactions 
were examined 
Franceschini 
et al. 
(1993) 
Adults with 
hypercholesterolemia, 
31-61 years 
Italy 10 No  Max 
3600 
Plasma lipids, 
plasma 
lipoproteins 
4 weeks 
per dose 
No adverse 
effects were 
recorded. No 
increase in 
lipoprotein 
concentrations 
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2.4.1.1 Randomised controlled trials (RCT) 
Efficacy and safety of N-acetylcysteine in prevention of noise induced hearing 
loss: A randomized clinical trial. Kopke et al., 2015 
In this randomised, double-blind, placebo controlled trial NAC was given to prevent noise 
induced hearing loss in US military personnel (Kopke et al., 2015). Safety was a pre-specified 
outcome of this study that enrolled 566 subjects and randomised them into daily NAC 
(2700 mg) or placebo for 16 days. There were small positive and borderline significant 
effects on the hearing measurements. NAC was not associated with (mild or severe) adverse 
effects. The study participants completed questionnaires regarding adverse events prior to 
weapons training on each of the 16 days of dosing, and at study completion (approximately 
10 days after their last dose). The principal investigator and medical monitor each received 
daily reports of subject adverse events and medical clinic visits for immediate review and 
determination of the subject's medical needs and ability to continue in the study. 
The efficacy of N-acetylcysteine in the treatment of methamphetamine 
Dependence: A Double-blind Controlled, Crossover Study. Mousavi et al., 2015 
This was a double blind crossover trial in 32 methamphetamine dependent volunteers who 
were randomised to receive 1200 mg NAC or placebo (Mousavi et al., 2015). Following a 
wash out period of three days, all participants changed to the alternative treatment. Twenty-
three participants completed the study. Adverse events were self-reported and only mild 
adverse events were observed. The frequency of these events was not different according to 
placebo or NAC administration.  
The efficacy of adjunctive N-acetylcysteine in major depressive disorder: A 
double-blind, randomized, placebo-controlled trial. Berk et al., 2014 
In this study 269 patients with severe depressive symptoms were randomised to receive 2 g 
NAC or placebo daily (Berk et al., 2014). The mean age of the patients was approximately 50 
years. The participants randomised to NAC experienced more often mild gastrointestinal 
symptoms and musculoskeletal pain than the placebo group. Adverse events were self-
reported, three participants (two placebo and one in the NAC group) withdrew because of 
non-severe adverse events. NAC was not associated with increased risk of severe adverse 
events. 
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive 
pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled 
trial. Zheng et al., 2014 
This is the largest included randomised, placebo-controlled trial on the effect of NAC. From 
34 hospitals in China, 1006 patients with chronic obstructive pulmonary disease (COPD) were 
randomised to receive placebo or 1200 mg NAC daily for a year (Zheng et al., 2014). The 
mean age of the study participants was 67 years. According to the authors, adverse events 
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were monitored carefully and 26% of the participants in the placebo group and 29% in the 
NAC group experienced adverse events, however serious adverse events was more common 
in the placebo group than in the NAC group. It should be noted that these differences did 
not reach statistical significance.  The most frequently reported serious adverse event was 
severe COPD, which was an outcome of the trial. Other severe adverse events were coronary 
artery disease, cerebral infarction, lower respiratory infections, upper respiratory tract 
infection, and osteoarthopathy. No notable laboratory abnormalities were reported, however, 
they did not mention which laboratory parameters that were recorded.  
High-dose N-acetylcysteine in stable COPD. The 1-year, double-blind, 
randomized, placebo-controlled HIACE study. Tse et al., 2013 
In Hong Kong, 120 patients with COPD were randomised to receive placebo or 600 mg daily 
for one year (Tse et al., 2013). The mean age of the participants was 71 years. Self-reported 
adverse events were recorded and there was no increase in incidence of adverse events with 
NAC, no severe adverse event occurred in either group. The most common adverse events 
reported were GI discomfort including diarrhea and gastroesophageal reflux disease 
symptoms. Three patients died during the year NAC was given: one receiving placebo and 
two receiving NAC and all three were unrelated to this treatment.  
A double-blind randomized controlled trial of N-acetylcysteine in cannabis-
dependent adolescents. Gray et al., 2012 
Cannabis dependent adolescents aged 15-21 years of age were randomised to receive 
2400 mg NAC or placebo daily for eight weeks (Gray et al., 2012). The main outcome of this 
double-blind, randomised placebo-controlled trial was to measure the efficacy of NAC on 
abstaining from cannabis use. Adverse events were recorded through an open-ended 
interview. There were no FDA-defined serious adverse events, and there were no significant 
differences between the two treatment groups in the occurrence of any adverse events (38 
events in the NAC group and 46 events in the placebo group). The most common adverse 
event was upper respiratory infection, which occurred in 19 participants (11 in the NAC 
group and eight in the placebo group).  
A randomized controlled pilot trial of oral N-acetylcysteine in children with 
autism. Hardan et al., 2012 
Thirty-four children (3-11 years) with autism were randomised to receive placebo or NAC in 
increasing doses from 900 mg at study start till 2700 mg over a 12-week period (Hardan et 
al., 2012). Main outcome was autism symptoms measured by standard scales. Adverse 
events were recorded by a standardised, structured questionnaire. Oral NAC was well 
tolerated with limited side effects. Most adverse effects were gastrointestinal and with a 
slightly higher non-significant incidence among the NAC participants. 
 
  
VKM Report 2015: 20  28 
N-Acetylcysteine in handgrip exercise: plasma thiols and adverse reactions. 
Ferreira et al., 2011. 
In this experiment 17 participants were divided into two groups who were given NAC 
capsules or NAC solutions at different doses (Ferreira et al., 2011). The highest dose was 
140 mg/kg (i.e. 9800 mg in an individual of 70 kg). The main outcome of the study was to 
measure the response of the different doses of NAC on plasma thiol availability and on the 
performance of a “handgrip exercise”. The report did not explicitly define the primary and 
secondary outcomes of the experiment. Each dose was only given once and adverse 
reactions were observed for maximum three days. Subjects completed a questionnaire about 
adverse reactions experienced during the trial. The intensity of adverse reactions was mostly 
mild, but some individuals experienced GI reactions of moderate intensity after the highest 
dose of NAC.  
A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients 
with cystic fibrosis. Dauletbaev et al., 2009 
Twenty one patients with cystic fibrosis with a mean age of 28 years were randomised to 
receive 700 or 2800 mg NAC daily for 12 weeks (Dauletbaev et al., 2009). No study 
participants were given placebo only. The clinical efficacy was similar for these two doses 
and the high dose did not result in higher rates of adverse events. Several adverse events as 
well as markers of inflammation and liver function were recorded in this study. However, the 
power to detect differences between the groups was low and the effects on the biochemical 
parameters listed in the methods were not reported in the results. 
N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A 
double-blind, placebo-controlled study. Grant et al., 2009 
In this double blind, placebo controlled trial that lasted for 12 weeks, 50 individuals (mean 
age 34.3 years) with trichotillomania were randomised to receive 1200 to 2400 mg of NAC 
per day throughout the study period (Grant et al., 2009). The main outcome of the study 
was the effect of NAC on trichotillomania. Safety assessments at each visit included 
evaluations of blood pressure, heart rate, and weight. Adverse effects were documented and 
included time of onset and resolution, severity, action taken, and outcome. No adverse 
events occurred in the NAC group, and NAC was well tolerated.  
N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia-A Double-Blind, 
Randomized, Placebo-Controlled Trial. Berk et al., 2008 
In this study 140 schizophrenia patients with an average age of 36.5 years were randomised 
to placebo or 1000 mg NAC daily for 24 weeks (Berk et al., 2008a). Adverse effects were 
self-reported; there were no increased risk of adverse events in the group receiving NAC.  
 
  
VKM Report 2015: 20  29 
N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder-A Double-Blind 
Randomized Placebo-Controlled Trial. Berk et al., 2008 
In this RCT, 75 patients with an average age of approximately 45 years were randomised to 
receive 2000 mg NAC or placebo daily for 12 weeks (Berk et al., 2008b). Adverse events 
were self-reported and included fatigue (21% NAC, 27% placebo), headaches (18% NAC, 
8% placebo), heartburn (16% NAC, 8% placebo), and increased pain in joints (16% NAC, 
8% placebo). No reported event was significantly more common in the NAC group compared 
with the placebo group. There were seven serious adverse events reported during the study, 
three were in the NAC group and four were in the placebo group. All were hospitalisations, 
and all, except a victim of a motorcycle accident, were due to deteriorations in mental state.  
Effect of oral N-acetylcysteine in COPD - A randomised controlled trial. Bachh et 
al., 2007 
One hundred patients with COPD were given 600 mg NAC or placebo every day for one year 
(Bachh et al., 2007). The main outcome of this trial was lung function measured by 
spirometry and number of exacerbations. The authors reported that there were no adverse 
effects related to NAC. However, it was not stated which adverse effects were measured and 
how this was done. 
Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. 
LaRowe et al., 2006 
This crossover study included 11 cocaine dependent individuals who were given 1200 mg 
NAC or placebo daily during a three-day hospital stay (LaRowe et al., 2006). Each participant 
was hospitalised twice and randomised to receive either of the treatments during each stay. 
NAC was well tolerated, no severe adverse effects were reported and there were no 
differences in adverse effects between the study groups. The manuscript does not give a 
good description of the design and does not include a figure that indicates the flow of 
participants through the study. It was not easy to identify the duration of the intervention, 
the daily dose, as well as the total number of participants of the study.  
High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive 
pulmonary disease. Zuin et al., 2005 
In this randomised, double blind placebo controlled trial 123 patients with COPD (mean age 
67 years) were randomised in a 1:1:1 ratio to receive placebo, 600, or 1200 mg NAC daily 
for 10 days (Zuin et al., 2005). Very few, and no severe, adverse events were observed and 
they were not associated with NAC. Furthermore, no significant changes were observed in 
vital signs, blood chemistry, whole blood cell count or urinalysis. It is however, unclear how 
the adverse effects were recorded and which parameters were included in the laboratory 
assessments.  
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N-acetylcysteine reduces the exacerbation rate in patients with moderate to 
severe COPD. Pela et al., 1999 
In this study 169 patients with COPD were randomised to receive placebo or NAC (600mg) 
daily for six months (Pela et al., 1999). NAC treatment resulted in a substantial and 
significant improvement in lung function and a reduction of exacerbation rate. The study 
apparently monitored adverse effects carefully; however, how these were registered is not 
clearly described. The events were self-reported and none were severe or related to NAC.  
Attenuation of influenza-like symptomatology and improvement of cell-mediated 
immunity with long-term N-acetylcysteine treatment. De Flora et al., 1997 
Two hundred and sixty two Italian elders were recruited from 20 medical centres and 
randomised in a 1:1 ratio to receive 1200 mg NAC or placebo for six months, the main 
outcome of the trial was the incidence of influenza (De Flora et al., 1997). NAC was well 
tolerated and there were no serious adverse events and not a significantly increased risk of 
self-reported adverse events in the NAC group. None of the laboratory end-points monitored 
and main vital parameters, such as cardiac frequency and arterial pressure, were different 
between the groups following the intervention. However, the authors only refer to “routine 
haematological and biochemical parameters” and do not mention the actual biomarkers 
assessed. 
2.4.1.2 Other human studies 
Respiratory paradoxical adverse drug reactions associated with acetylcysteine 
and carbocysteine systemic use in paediatric patients: A national survey. Mallet et 
al., 2011 
In this French survey, the safety of acetylcysteine in childhood respiratory infection was 
assessed using voluntary case reports from French physicians between 1989 and 2008 
(Mallet et al., 2011). In 2010, the French drug agency, and then the Italian drug agency, 
withdrew the licenses for children younger than two years old for NAC because their use was 
associated with paradoxically increased bronchorrhea (increased secretions from the 
peripheral airways) and acute respiratory distress during respiratory tract infections. In this 
survey they analysed the data for 30 cases of paradoxical respiratory adverse drug reactions 
in children younger than six years after an exposure of >200 mg NAC. They concluded 
“Parents, physicians, pharmacists, and drug regulatory agencies should know that the 
benefit risk ratio of mucolytic drugs is at least null and most probably negative in infants 
according to available evidence”. 
Dose-related increase of HDL-cholesterol levels after N-acetylcysteine in man. 
Franceschini et al., 1993 
In this study 10 hypercholesterolic patients (age 31-61 years) were given graded doses 
(1200, 2400 and 3600 mg) of NAC daily for four weeks and plasma lipids and lipoproteins 
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were measured after the three four week regimes (Franceschini et al., 1993). Plasma total, 
very low density lipoprotein (VLDL) and low density lipoprotein (LDL) cholesterol and 
triglyceride concentrations were not affected by either of the NAC doses. However, high 
density lipoprotein (HDL) cholesterol increased progressively by increasing NAC doses. The 
authors concluded that the study “failed to note any significant change in plasma lipoprotein 
(a) levels, even after very high daily doses of NAC”.  
2.4.1.3 Meta analyses 
Acetylcysteine and carbocysteine for acute upper and lower respiratory tract 
infections in paediatric patients without chronic broncho-pulmonary disease 
(Cochrane Review). Chalumeau and Duijvestijn, 2013 
Efficacy and safety of NAC have been evaluated in a Cochrane meta-analysis and concluded: 
“This report included the results from nine controlled trials where acetylcysteine was given 
orally at doses up to approximately 500 mg per day for up to 14 days. The trials that 
reported safety studied clinical or biological tolerance, or both. The biological tests consisted 
usually of full blood tests and the monitoring of hepatic and renal function. In two studies, 
safety was also evaluated using radiographic or pulmonary function tests. The included 
studies all showed good clinical safety, except mild gastrointestinal tract adverse events and 
vomiting (Chalumeau and Duijvestijn, 2013).  
2.4.1.4 Interactions, allergic sensitisation and adjuvant effects  
Treatment with NAC may strengthen the effects of immune suppressants, such as 
azathioprine, cyclophosphamide, or prednisone. L-cysteine should be used with caution with 
these medications and such combinations should be discussed with the doctors. 
Nitroglycerin and isosorbide: NAC may strengthen the effect of nitroglycerin and 
isosorbide; two medications commonly used to angina pectoris. But this combination may 
also raise the risk of side effects, such as severe headache, and may lead to abnormally low 
blood pressure.  
Anaphylactoid reactions have been observed when oral NAC has been given in high doses for 
treatment of paracetamol toxicity. These reactions have been considered nonimmunological 
and accordingly not classified as allergic. The gastrointestinal side effects may also, in part, 
be mediated though the same mechanisms and not by an allergic reaction to NAC or L-
cysteine. 
 Animal studies 2.4.2
According to ANSES, animal studies have shown that high doses cysteine can result in fatty 
liver and hypercholesterolemia and that it can be neurotoxic in young rodents (ANSES, 
2011). However, subsequent animal studies have not been able to reproduce this adverse 
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effect of cysteine containing compounds on lipid metabolism or hypercholesterolemia (Korou 
et al., 2014; Lin and Yin, 2008). 
 Mode of action for adverse effects  2.4.3
Except for the anaphylactoid reactions related to high doses of NAC, no specific or definite 
mechanism for adverse effects have been described. 
 Vulnerable and high intake groups 2.4.4
No tolerance level is set for cysteine or cystine specifically for children or adolescents, but an 
assumption is made that these age groups have similar tolerance as adults. 
NAC may enhance the effect of nitroglycerin and isosorbide; two medications commonly 
used to angina pectoris. But this combination may also raise the risk of side effects, such as 
severe headaches, and may lead to abnormally low blood pressure.  
In the hereditary disease cystinuria, kidney stones are formed from circulating cystine. 
People with this disease should consult their physician before they take supplemental 
cysteine or cystine. 
In the included literature, no information was available about other vulnerable groups from 
human studies, including pregnant or nursing women. 
2.5 Summary of hazard identification and characterisation 
There are several RCTs that have measured the efficacy of NAC at relatively high doses for 
up to one year. The study groups have been various patient groups ranging from children, 
adolescents, adults and elderly, but also some healthy subjects. In the RCTs there were no 
differences in severe adverse events between the placebo and NAC-groups. The following 
adverse effects were investigated: dizziness, fatigue, energy level, gastrointestinal 
discomfort, allergic reactions and muscle pain among others. In most of the studies, the 
results for adverse effects were based on self-reporting systems or clinical examination. A 
few studies also included analyses of biomarkers from blood or urine samples.  
The majority of the studies have been conducted in adults. The included studies demonstrate 
that it is well documented that the dose 1200 mg, and in some studies even up to 2400 mg 
NAC per day, do not cause adverse effects. These doses of NAC correspond to 900 and 
1800 mg of cysteine and cystine. This is equivalent to 13 and 26 mg cysteine or cystine per 
kg bw in an adult per day (70 kg as default weight). In the large, recent study by Zheng et 
al. (2014), where 1200 mg NAC (i.e. 900 mg cysteine) or placebo was given daily for a year 
to 1000 people, NAC was not associated with increased risk of severe adverse events. These 
results correspond with those of the other RCTs using NAC.  
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Studies with doses of 500 mg NAC have been conducted in children (corresponding to 
375 mg cysteine or cystine). The few studies that included children and adolescents were of 
relatively short duration. 
Animal studies have shown that high doses can result in fatty liver and hypercholesterolemia 
and that it can be neurotoxic in young rodents. There are, to our knowledge, no reports from 
studies in humans that confirm these findings. On the contrary, we were able to identify one 
study that demonstrated that NAC in increasing doses increased the levels of HDL while not 
affecting the concentration of other lipoproteins and lipids.  
Animal studies included in previous reports with high doses of cysteine over six generations 
in rats found a NOAEL of 175 mg/kg bw/day at the highest dose. 
As value for comparison used in the risk characterisation of cysteine and cystine, VKM will 
use 900 mg/day corresponding to 13 mg/kg bw/day. This is based on doses used in many 
studies in various population groups. 
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3 Exposure / Intake 
Exposure of cysteine and cystine was estimated from the intake of food supplements. For 
food supplements, the intake of cysteine and cystine was estimated for the age groups 10-
14 years, 14-18 years and adults (≥18 years).  
3.1 Food supplements 
The Norwegian Food Safety Authority has requested a risk assessment of 10 mg/day 
cysteine and 250, 500, 750 and 1000 mg/day cystine in food supplements for children 10 
years and above, adolescents and adults. The default body weights (bw) for age groups 
determined by the EFSA were used: 10 to <14 years=43.4 kg, 14 to <18 years=61.3 kg, 
and adults=70 kg. The intakes per kg bw is given in (Table 3.1-1). 
Table 3.1-1: Estimated exposure of cysteine or cystine from specified doses in food supplements in 
children, adolescents and adults. 
Groups Daily 
doses, mg 
Body weight Exposures (mg/kg bw per day) 
Children (10 to <14years) 10, 250, 500, 
750 and 
1000 
43.4 0.2, 6, 12, 17 and 23 
Adolescent (14 to <18 
years) 
10, 250, 500, 
750 and 
1000 
61.3 0.2, 4, 8, 12 and 16 
Adults (≥18 years) 10, 250, 500, 
750 and 
1000 
70.0 0.1, 4, 7, 11 and 14 
3.2 Other sources 
Based on distribution data from the 1988–1994 National Health and Nutrition Examination 
Survey (NHANES III), the common mean daily intake for all life stage and gender groups of 
cysteine is 1.0 g/day in USA. Men 51 through 70 years of age had the highest intakes at the 
99th percentile of 2.2 g/day (IOM, 2005). 
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4 Risk characterisation  
The doses received from NFSA are 10 mg/day L-cysteine and 250, 500, 750 and 
1000 mg/day L-cystine in food supplements, and the exposures for adults, adolescents and 
children above 10 years are given in chapter 3.  
The value for comparison used in this risk characterisation is 900 mg/day (corresponding to 
13 mg/kg bw/day in a 70 kg adult). 
The few studies that included children and adolescents were of relatively short duration. 
However, there are no data indicating that children and adolescent are more vulnerable than 
adults for cysteine or cystine. No tolerance level is set for cysteine or cystine specifically for 
children or adolescents. Assuming similar tolerance for these age groups as for adults, doses 
below 13 mg/ kg bw in children and adolescents are considered to be unlikely to cause 
adverse health effects. 
VKM considers that: 
In adults (≥18 years), the specified doses 10 mg/day L-cysteine and 250, 500 and 
750 mg/day L-cystine in food supplements are considered to be unlikely to cause adverse 
health effects, whereas the dose 1000 mg L-cystine per day may represent a risk of adverse 
health effects. 
In adolescents (14 to <18 years), the specified doses 10 mg/day L-cysteine and 250, 500 
and 750 mg/day L-cystine in food supplements are considered to be unlikely to cause 
adverse health effects in adolescents, whereas the dose 1000 mg L-cystine per day may 
represent a risk of adverse health effects. 
In children (10 to <14 years), the specified doses 10 mg/day L-cysteine and 250 and 
500 mg/day L-cystine in food supplements are considered to be unlikely to cause adverse 
health effects, whereas the doses 750 and 1000 mg L-cystine per day may represent a risk 
of adverse health effects   
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5 Uncertainties 
All of the human studies included in this report are from randomised placebo controlled trials 
with NAC. NAC is an acetylated and stable form of cysteine and we have assumed that it has 
identical biological properties as cysteine and cystine. 
Similarly, cystine consists of two cysteine molecules covalently bound to each other via a 
disulfide bond. Cystine is stable and is metabolised to two cysteine molecules intracellularly. 
We have therefore also assumed cystine and cysteine to have identical biological properties, 
which may not be appropriate in all circumstances. 
Several of the studies referred to are RCTs, specifically designed to investigate the positive 
effects of NAC, and not negative effects. Adverse effects are reported, but often based on 
self-reporting questionnaires or physical examination, and to a lesser extent biomarkers for 
negative health effects e.g. blood lipids. 
There is a lack of studies that have measured the effect of high doses for longer periods. 
The longest, randomised placebo controlled trials that have measured the effect of daily 
administration of NAC at doses of 1200 mg per day have been carried out for six to 12 
months and there have, to our knowledge, been no attempts to measure adverse or 
beneficial effects beyond the time of supplementation. The data for children and adolescents 
are more scarce than for adults. 
Animal studies have shown that high doses can result in fatty liver and hypercholesterolemia 
and that it can be neurotoxic in young rodents. There are, to our knowledge, no reports from 
studies in humans that confirm these findings.  
There is also a risk that our search strategy has failed to identify studies that have reported 
adverse events as not all RCTs report adverse events in a similar manner and according to 
existing guidelines such as those suggested by the “Consort group” (http://www.consort-
statement.org). 
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6 Data gaps 
There is a lack of studies of adverse effects as primary outcomes of cysteine and cystine in 
humans. The studies which have reported negative health effects related to NAC in adults 
have high heterogeneity both in design, target population, and results.  
There are few studies on negative health effects related to NAC or L-cysteine / L-cystine in 
children and adolescents. 
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7 Conclusions with answers to the 
terms of reference 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of L-cysteine and L-cystine in food supplements 
at the following doses: L-cysteine 10 mg and L-cystine 250, 500, 750 and 1000 mg/day for 
the general population, ages 10 years and above. 
In adults, it is well documented that doses up to 900 mg per day L-cysteine or L-cystine for 
one year is unlikely to cause adverse health effects. The adverse effects reported in a small 
number of subjects in human studies are generally limited to mild gastrointestinal 
discomfort. Data for doses above 900 mg/day are more scarce. 
Studies on children (10-14 years) and adolescents (14-18 years) were identified. Based on 
these there was no evidence indicating that children or adolescents are more vulnerable than 
adults for cysteine or cystine. Therefore, in this risk characterisation a tolerance as for 
adults, based on body weight, were assumed for these age groups. 
We were not able to identify any particular vulnerable groups. However it is possible that 
cysteine or cystine can modify the effect of certain drugs such as nitroglycerin. The extent to 
which this represents a risk for individuals on these drugs is uncertain. 
VKM concludes that: 
 In adults (≥18 years), the specified doses 10 mg/day L-cysteine and 250, 500 and 
750 mg/day L-cystine in food supplements are considered to be unlikely to cause 
adverse health effects, whereas the dose 1000 mg L-cystine per day may represent a 
risk of adverse health effects. 
 In adolescents (14 to <18 years), the specified doses 10 mg/day L-cysteine and 250, 
500 and 750 mg/day L-cystine in food supplements are considered to be unlikely to 
cause adverse health effects in adolescents, whereas the dose 1000 mg L-cystine per 
day may represent a risk of adverse health effects. 
 In children (10 to <14 years), the specified doses 10 mg/day L-cysteine and 250 and 
500 mg/day L-cystine in food supplements are considered to be unlikely to cause 
adverse health effects, whereas the doses 750 and 1000 mg L-cystine per day may 
represent a risk of adverse health effects.  
An overview of the conclusions is presented in Table 6.1.  
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Table 6.1: An overview of the conclusions for L-cysteine and L-cystine in food supplements.  
Green: Estimated exposures to L-cysteine and L-cystine are unlikely to cause adverse health effects. 
Red: Estimated exposures to L-cystine may represent a risk of adverse health effects. 
 L-Cysteine L-Cystine 
Doses 
Age groups 
10 
mg/day 
250 
mg/day 
500 
mg/day 
750 
mg/day 
1000 
mg/day 
Children  
(10 to <14 years) 
        
Adolescents  
(14 to <18 years) 
        
Adults (≥18 years) 
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9 Appendix 
Search strategy for this risk assessment: 
-------------------------------------------------------------------------------- 
1. (cystein* or l cysteine* or cystin* or acetylcystein* or n acetylcystein* or n acetyl 
cysteine*).ti. (51581) 
2. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or negative or 
contraindicat* or contra-indicat* or interact* or toxicity or toxic).tw. (9677036) 
3. 1 and 2 (10038) 
4. (homocysteine* not (homocysteine* and (cystein* or cystin* or acetylcystein* or n 
acetylcystein* or n acetyl cystein*))).mp. (48526) 
5. 3 not 4 (10038) 
6. (conference abstract* or letter* or editorial*).pt. (4356439) 
7. 5 not 6 (9497) 
8. limit 7 to (danish or english or norwegian or swedish) (9180) 
9. limit 8 to human [Limit not valid in Global Health; records were retained] (4050) 
10. remove duplicates from 9 (2525) 
 
